The MXI1 Knockout Raji Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji human B lymphocyte line, engineered for loss-of-function studies of the MXI1 transcriptional repressor. Target-gene disruption eliminates functional MXI1 protein, providing a robust model to dissect its role within the MYC-MAX regulatory network. This polyclonal population is suitable for experiments requiring a heterogeneous knockout background, without clonal selection artifacts, and is designed for advanced biomedical research applications spanning cancer biology, signal transduction, and drug discovery.
The Raji host cell line, established from a Burkitt lymphoma patient, is a widely employed B lymphoblastoid model characterized by Epstein-Barr virus (EBV) positivity and constitutive c-MYC overexpression due to a chromosomal translocation. As an antibody-producing and antigen-presenting B lymphocyte, Raji cells are foundational in immunology, virology, and lymphomagenesis research. Their aggressive growth phenotype, driven by deregulated MYC activity, makes them particularly valuable for investigating mechanisms of B-cell malignancies and MYC-dependent transformation.
MXI1 is a member of the MAD family of basic helix-loop-helix leucine zipper transcriptional repressors. It antagonizes MYC oncogenic activity by competitively binding to the obligate partner MAX, thereby forming MXI1-MAX heterodimers that recruit corepressor complexes including SIN3A and histone deacetylase HDAC1 to repress transcription of MYC target genes. Upstream, MXI1 expression is regulated by TGF-??1, p53, and SMAD2/SMAD3 signaling, linking it to growth inhibitory and apoptotic pathways. Its downstream targets include CCND2, CDKN1A (p21), CDKN1B (p27), and TERT, key regulators of cell cycle progression and proliferation. Additionally, MXI1 interacts with factors such as MAD1 and MLX, integrating signals through the TGF-?? and p53 pathways to maintain cellular homeostasis.
Disruption of MXI1 in the MYC-overexpressing Raji background removes a critical brake on MYC-dependent transcription, leading to enhanced expression of proliferation-promoting genes and altered apoptotic responses. This knockout model mirrors aggressive B-cell lymphoma scenarios where MXI1 silencing or loss-of-function mutations occur. It provides a physiologically relevant system to study how the balance between MYC and its antagonists governs lymphomagenesis, tumor progression, and sensitivity to targeted therapies. The model is particularly apt for exploring synthetic lethal interactions and resistance mechanisms to MYC inhibitors.
Researchers can employ these MXI1 knockout polyclonal Raji cells for a diverse array of experimental strategies. Functional analyses include Western blotting to confirm target-gene disruption and assess MYC target protein levels, RT-qPCR profiling of downstream genes, and cell proliferation assays to quantify growth advantages. Drug sensitivity screening with MYC pathway inhibitors (e.g., BET bromodomain inhibitors) can identify therapeutic vulnerabilities. Apoptosis induction studies via flow cytometry, combined with RNA-seq transcriptomic profiling, reveal pathway alterations. Additionally, ChIP-qPCR enables mapping of MYC/MXI1 occupancy changes at target loci. For further details, trial options, or quote requests, we invite you to contact Ascent Research.
